At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INKT MiNK Therapeutics, Inc.
Post-Mkt 11-02 16:34:19 EST
11.04
+0.51
+4.84%
盘后10.63
-0.41-3.71%
16:10 EST
High11.48Low10.41Vol11.56K
Open10.41D1 Closing10.53Amplitude10.16%
Mkt Cap56.34MTradable Cap22.77MTotal Shares5.10M
T/O126.44KT/O Rate0.56%Tradable Shares2.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MiNK Therapeutics Price Target Raised to $50.00/Share from $43.00 by B. Riley Securities
Dow Jones  ·  10-21
MiNK Therapeutics Price Target Raised to $50.00/Share from $43.00 by B. Riley Securities
B. Riley Adjusts Price Target on MiNK Therapeutics to $50 From $43, Maintains Buy Rating
MT Newswires Live  ·  10-21
B. Riley Adjusts Price Target on MiNK Therapeutics to $50 From $43, Maintains Buy Rating
MiNK Therapeutics management to meet virtually with B. Riley
TIPRANKS  ·  10-13
MiNK Therapeutics management to meet virtually with B. Riley
MiNK Therapeutics Highlights Phase 2 Trial Testing agenT-797 with Botensilimab and Balstilimab in MSS Colorectal Cancer Liver Metastases
Reuters  ·  10-02
MiNK Therapeutics Highlights Phase 2 Trial Testing agenT-797 with Botensilimab and Balstilimab in MSS Colorectal Cancer Liver Metastases
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
GlobeNewswire  ·  10-02
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy
TIPRANKS  ·  09-30
MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy
MiNK Therapeutics iNKT Platform Joins ARPA-H-Funded Room-Temperature Cell Therapy Program
Reuters  ·  09-30
MiNK Therapeutics iNKT Platform Joins ARPA-H-Funded Room-Temperature Cell Therapy Program
Mink Therapeutics - Arpa-H Commits up to $87 Mln to Four-Year Boss Program
THOMSON REUTERS  ·  09-30
Mink Therapeutics - Arpa-H Commits up to $87 Mln to Four-Year Boss Program
Mink Therapeutics Selected for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy
THOMSON REUTERS  ·  09-30
Mink Therapeutics Selected for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
Reuters  ·  08-13
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
Benzinga Earnings  ·  08-13
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics Q2 EPS USD -0.62
Reuters  ·  08-13
MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury
THOMSON REUTERS  ·  08-13
Mink Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury
Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
Dow Jones  ·  08-13
Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
Mink Therapeutics Inc Expected to Post a Loss of 60 Cents a Share - Earnings Preview
Reuters  ·  08-11
Mink Therapeutics Inc Expected to Post a Loss of 60 Cents a Share - Earnings Preview
Mink Therapeutics - First Agent-797 Patients Alive and Afebrile at Day 28 with Improved Oxygenation
THOMSON REUTERS  ·  08-07
Mink Therapeutics - First Agent-797 Patients Alive and Afebrile at Day 28 with Improved Oxygenation
Mink Therapeutics - no Major Serious Adverse Events Attributed to Agent-797 in First Patients
THOMSON REUTERS  ·  08-07
Mink Therapeutics - no Major Serious Adverse Events Attributed to Agent-797 in First Patients
Mink Therapeutics - Enrollment Continues in Lviv with U.S. Sites Opening; Additional Data Expected Early 2027
THOMSON REUTERS  ·  08-07
Mink Therapeutics - Enrollment Continues in Lviv with U.S. Sites Opening; Additional Data Expected Early 2027
MiNK Therapeutics Reports Early Phase 2 Data for agenT-797 in Severe Hypoxemic Pneumonia Trial
Reuters  ·  08-07
MiNK Therapeutics Reports Early Phase 2 Data for agenT-797 in Severe Hypoxemic Pneumonia Trial
Mink Therapeutics to Report Q2 Results, Host Conference Call and Webcast
Reuters  ·  08-06
Mink Therapeutics to Report Q2 Results, Host Conference Call and Webcast

Introduction

Company Name.
MiNK Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Issue price:
--